Skip to main content

Table 2 Relationship between overall survival and clinicopathological variables

From: The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

Variable n Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Gender Male 61 1 (reference) 0.657   
Female 12 0.807 (0.313–2.080)  
Age (y) < 65 26 1 (reference) 0.422   
≥ 65 47 1.340 (0.656–2.738)  
Performance status 0 or 1 57 1 (reference) 0.004 a 1 (reference) 0.066
2 16 2.975 (1.431–6.186) 2.051 (0.954–4.410)
Body surface area (m2) < 1.50 30 1 (reference) 0.162   
≥ 1.50 43 1.664 (0.815–3.398)  
eGFR (ml/min/1.73m2) < 60 13 1 (reference) 0.838   
≥ 60 60 1.096 (0.455–2.643)  
Tumor size (cm) < 5 35 1 (reference) < 0.001 a 1 (reference) 0.332
≥ 5 38 3.755 (1.784–7.903) 1.638 (0.605–4.436)
Post-dCRT chemotherapy 17 1 (reference) 0.646   
+ 56 0.823 (0.358–1.891)  
Histological type Differentiated 64 1 (reference) 0.876   
Un-differentiated 9 1.079 (0.418–2.782)  
Clinical stage in UICC 8th edition I (cT1b) - III 38 1 (reference) < 0.001 a 1 (reference) 0.006 a
IVA or IVB (cM1-lym) 35 5.177 (2.448–10.946) 4.085 (1.488–11.211)
Radiation dose (Gy) < 57 13 1 (reference) 0.670   
≥ 57 60 1.229 (0.477–3.169)  
Nedaplatin dose intensity in dCRT (%) < 90 45 1 (reference) 0.360   
≥ 90 28 0.716 (0.351–1.463)  
5-fluorouracil dose intensity in dCRT (%) < 90 47 1 (reference) 0.130   
≥ 90 26 0.556 (0.261–1.188)  
SLFN11 expression Low (< 51) 37 1 (reference) 0.018 a 1 (reference) 0.001 a
(H-score) High (≥ 51) 36 0.438 (0.221–0.866) 0.295 (0.143–0.605)
  1. Abbreviations: HR hazard ratio, CI confidence interval, eGFR estimated glomerular filtration rate, cM1-lym distant lymph node metastasis, dCRT definitive chemoradiotherapy, H-score histo-score
  2. astatistically significant
\